Join Growin Stock Community!

Impact biomedical inc.IBO.US Overview

US StockHealthcare
(No presentation for IBO)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

IBO AI Insights

IBO Overall Performance

IBO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

IBO Recent Performance

-1.38%

Impact biomedical inc.

0.05%

Avg of Sector

-0.31%

S&P500

IBO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

IBO Key Information

IBO Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

IBO Profile

Impact BioMedical Inc. engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. It provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. The company also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, it develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications. The company was incorporated in 2018 and is based in Houston, Texas.

Price of IBO

IBO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

IBO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.54
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1821.66
PB Ratio
1.24
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
52.00%
Net Margin
-176764.00%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.54
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1821.66
PB Ratio
1.24
Price-to-FCF
-
Gross Margin
52.00%
Net Margin
-176764.00%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is IBO's latest earnings report released?

    The most recent financial report for Impact biomedical inc. (IBO) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IBO's short-term business performance and financial health. For the latest updates on IBO's earnings releases, visit this page regularly.

  • What is the operating profit of IBO?

    According to the latest financial report, Impact biomedical inc. (IBO) reported an Operating Profit of -948K with an Operating Margin of -5,266.67% this period, representing a growth of 15.88% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is IBO's revenue growth?

    In the latest financial report, Impact biomedical inc. (IBO) announced revenue of 18K, with a Year-Over-Year growth rate of 0%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does IBO have?

    At the end of the period, Impact biomedical inc. (IBO) held Total Cash and Cash Equivalents of 12K, accounting for 0 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does IBO go with three margins increasing?

    In the latest report, Impact biomedical inc. (IBO) did not achieve the “three margins increasing” benchmark, with a gross margin of 94.4%%, operating margin of -5,266.67%%, and net margin of -8,166.7%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess IBO's profit trajectory and future growth potential.

  • Is IBO's EPS continuing to grow?

    According to the past four quarterly reports, Impact biomedical inc. (IBO)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.12. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of IBO?

    Impact biomedical inc. (IBO)'s Free Cash Flow (FCF) for the period is -613K, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 52.3% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.